Client references
Immunovia: € 4.25M
The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million.
Climate Recovery AB
The company has developed a highly innovative, pre-insulated HVAC (heating, ventilation and air conditioning) duct system based on mineral wool for the land & marine construction sectors. Climate Recocery was granted € 1,7 Million from the Horizon 2020 SME Instrument Phase 2 programme. “GAEU´s high level of technical knowledge provided assistance in articulating the…
Colzyx: € 2,5M
Colzyx has used GAEU for both the Phase 1 SME Instrument and the Phase 2 Accelerator – both applications were granted. We have found GAEU to be very professional, dedicated and skilled. In addition, the atmosphere in collaboration with GAEU has been characterized by openness and a strong commitment to creating the best possible project…
Cellink AB: € 2.5M
The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Cellink was granted € 2.5M from the SME Instrument HORIZON 2020, phase 2. “Collaborating with GAEU has been…
Cinnober: € 2.5M
We are very pleased with GAEU Consulting’s work! Together with GAEUs advisors, we have managed to win in fierce competition with other European companies.
Betagenon: € 1.8M
In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products.
Nelson Garden: € 1.2M
I really would like to recommend GAEU to anyone who is interested in applying for Horizon 2020 funding.
CombiGene AB: € 3.3M
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. CombiGene was granted €3.3 million from the SME Instrument HORIZON 2020, phase 2. “GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience…
SenzaGen: € 2.4M
At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds.
Corline Biomedical AB: € 2.3M
Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Coreline was granted € 2.3M from the SME Instrument HORIZON 2020, phase 2. “This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded…
About Gaeu
GAEU Consulting is a professional service consultancy specializing in advising innovative companies on how to obtain EU grants to projects and growth activities
News
GAEU Consulting supports Minalyze in securing EUR 4M from the European Innovation Council (EIC)
GAEU Consulting supports Minalyze in securing EUR 4M from the European Innovation Council (EIC)
GAEU Consulting supports Colzyx in securing EUR 1 M equity investment from the European Innovation Council Fund (EIC Fund)
GAEU Consulting supports Colzyx in securing EUR 1 M equity investment from the European Innovation Council Fund (EIC Fund)
2.7 MEUR to GAEU’s clients!
Eurostars February 2021 cut-off results
2.7 MEUR to GAEU’s clients!
New funding record for GAEU’s team in the most competitive Eurostars cut-off ever.
GAEU´s client IRRAS receives loan financing under European Guarantee Fund
GAEU Consulting´s client, the medical technology company IRRAS, signs €10 million loan financing deal with European Investment Bank.
Pressrelease 2nd of June 2020
In strong competition GAEU’s client Vicore Pharma Holding AB (publ) was awarded £ 1.5 million by the British charity LifeArc for a COVID-19 Phase II study with the drug candidate VP01. The study, named ATTRACT (Angiotensin II Type Two Receptor Agonist COVID-19 Trial), is targeting hospitalized patients treated with basic respiratory care, but not yet on mechanical ventilation. In close cooperation between the GAEU’s and Vicore’s team, the winning application was written in record time.
Articles
The EIC SME Instrument New Work Programme = new possibilities
Biopharmaceuticals: New frontier
Laser-like focus on return on capital? A revamped project selection procedure
FOLLOW US ON TWITTER
Contact us
